臺灣博碩士論文加值系統

摘 要
中風是一種具潛在致命的腦血管疾病，因此有許多研究都致力於中風的治療。最近的研究指出，sphingosine-1-phosphate (S1P) agonist能顯著降低缺血性中風所造成的腦受傷體積。然而，對於與S1P同屬於溶血磷脂質 (lysophospholipids, LPLs)的lysophosphatidic acid (LPA)，其對中風的治療效應，目前並無相關的討論。
本研究以大白鼠為實驗動物，探討LPA 1/3受器的agonist VPC31143 (VPC)是否對永久性中大腦動脈梗塞 (permanent middle cerebral artery occlusion, PMCAO)大白鼠腦組織具有神經保護的作用。我們首先建立一套大白鼠中大腦動脈梗塞的腦中風動物模式，然後將接受PMCAO手術的雄性大白鼠分成control、vehicle、high-dose VPC、及low-dose VPC四組。此四組大白鼠於手術30分鐘後，分別接受無處理、腹腔注射3%幼牛血清白蛋白(bovine serum albumin, BSA; 1mL/kg)、腹腔注射0.8 mg/kg/mL VPC、與腹腔注射0.25 mg/kg/mL VPC的處理。我們並於大白鼠中風24小時後，紀錄各組的存活率。以Garcia Score評量表評估各組大白鼠大腦的感覺與運動功能，並測量與計算各組大白鼠腦的中風腦體積，與中風體積對全腦體積比例。所得結果以統計方法分析各組間的死亡率、體感覺(somatosensory)與運動功能、及大腦中風體積比率的差異。
實驗結果分析顯示，VPC可顯著減少PMCAO大白鼠於中風24小時後的死亡率、減少中風後感覺與運動的缺損程度、並降低中風體積比例。此結果突顯LPA在中樞神經系統受損時之保護效應。而此保護機制可能是經由LPA受器所耦合的PI3K訊息傳遞路徑所達成。此假設的正確性，則有待日後於轉錄與轉譯階層的確認。

Abstract
Stroke is a potentially lethal cerebrovascular event. Many research studies devoted to the treatment of stroke. In a recent study, sphingosine-1-phosphate (S1P) has the function of reducing the brain infarct volume. However, no study has yet demonstrated that lysophosphatidic acid (LPA) has this function. LPA and S1P are thought to be the two functionally important LPLs with high structural similarity. Although the neuroprotective function of S1P in TIA rat was confirmed, the effects of LPA on the brain damage after ischemic stroke of animal remain unclear.
In this study we evaluated the neuroprotective effects of LPA1/3 receptor agonist (VPC31143; VPC) on rat brains subjecting to permanent middle cerebral artery occlusion (PMCAO). A reliable surgical model of rat PMCAO was first established. Thereafter, the animals were divided into control, vehicle, high-dose VPC, and low-dose VPC groups. The vehicle group received intraperitoneal (i.p.) injection of 3% bovine serum albumin (BSA; 1 ml/kg) 30 minutes after PMCAO surgery. The high-dose VPC and the low-dose VPC group respectively received 0.8 mg/kg and 0.25 mg/kg of i.p. injection of VPC (in 3% BSA) 30 minutes after PMCAO surgery. The mortality rate, infarct volume ratio, and the neurobehavioral outcome were measured 24 hours after PMCAO and statistically analyzed for the difference between treatments.
Analyses of the experimental results showed that VPC treatment significantly reduced the mortality rate and the infarct volume ratio of the rats 24 hours after PMCAO. The neurobehavioral scores also showed the improved outcome in stroke rats treated with VPC. The beneficial effect of VPC to the ischemic brain was thought to be mediated through the PI3K signal transduction pathway. Further studies at the transcriptional and the translational levels will further confirm this postulation.

目 錄
審定書…………………………………………………………………………… 2

中文摘要………………………………………………………………………… 3

英文摘要………………………………………………………………………… 4

前言……………………………………………………………………………… 5

材料與方法……………………………………………………………………… 10

結果與討論……………………………………………………………………… 19

結論……………………………………………………………………………… 27

參考文獻………………………………………………………………………… 28

表格……………………………………………………………………………… 33

圖形……………………………………………………………………………… 38

附錄……………………………………………………………………………… 42

1. 邱弘毅.腦中風之現況與流行病學特徵 台灣腦中風學會會刊 2008年，第15
卷，第3期 2-3。
2. J.W. Choi, D. R. Herr, et al. LPA Receptors: Subtypes and Biological Actions. Annu.
Rev. Pharmacol. Toxicol. 2010 50:157–186.
3. D.R. Herr, J. Chun Effects of LPA and S1P on the Nervous System and Implications
for Their Involvement in Disease. Curr. Drug Targets 2007 8: 155-167.
4. G. Tigyi Selective Ligands for Lysophosphatidic Acid Receptor Subtypes: Gaining
Control over the Endothelial Differentiation Gene Family. Mol. Pharmacol. 2011 60:
1161–1164.
5. D. M. Heringdorf, K. H. Jakobs Lysophospholipid receptors: Signalling,
pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys.
Acta 2007 923–940.
6. J. Jonkers, W. H. Moolenaar Mammary Tumorigenesis through LPA Receptor
Signaling. Cancer Cell 2009 15: 457-458.
7. M. Yang, W. W. Zhong et al. G protein-coupled lysophosphatidic acid receptors
stimulate proliferation of colon cancer cells through the b-catenin pathway. Proc. Natl.
Acad. Sci. U.S.A. 2005 102: 6027–6032.
8. B. de Vries, R.A. Matthijsen et al. Lysophosphatidic Acid Prevents Renal Ischemia29
Reperfusion Injury by Inhibition of Apoptosis and Complement Activation. Am. J.
Pathol. 2003 163:47–56.
9. O. Murch, M. Collin et al. Lysophosphatidic acid reduces the organ injury caused by
endotoxemia-A role for G-protein-coupled receptors and peroxisome
proliferators-activated receptor- Shock 2007 27: 48-54.
10. C. Zhang, D. L. Baker et al. Lysophosphatidic Acid Induces Neointima Formation
Through PPAR-g Activation. J. Exp. Med. 2004 199: 763–774.
11. A.L. Parrill Structural characteristics of lysophosphatidic acid biological targets.
Biochem. Soc. Trans. 2005 33:1366-1369.
12. T. M. McIntyre, A. V. Pontsler et al. Identification of an intracellular receptor for
lysophosphatidic acid (LPA): LPA is a transcellular PPARg agonist. Proc. Natl. Acad.
Sci. U.S.A. 2003 100: 131-136.
13. M. Okazaki, F. Kreiselb et al. Sphingosine 1-Phosphate Inhibits Ischemia
Reperfusion Injury Following Experimental Lung Transplantation. Am. J. Transplant.
2007 7: 751–758.
14. T. Iwasaki, S. Tsunemi et al. Role of sphingosine 1-phosphate signaling for the
pathogenesis of autoimmune diseases. Inflammation and Regeneration 2011 31:
175-183.
15. Y. Hasegawa, H. Suzuki et al. Activation of Sphingosine 1-Phosphate Receptor-1 by
30
FTY720 Is Neuroprotective After Ischemic Stroke in Rats. Stroke 2010 41:368-374.
16. A. Kehlen, R. Lautebach et al: IL-1b- and IL-4-induced down-regulation of autotaxin
mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis
(RA). Clin. Exp. Immunol. 2001 123:147-154.
17. J. H. Garcia, S. Wagner et al. Neurological Deficit and Extent of Neuronal Necrosis
Attributable to Middle Cerebral Artery Occlusion in Rats. Stroke 1995 26:627-635.
18. N. J. Spratt et al: Modification of the method of thread manufacture improved stroke
induction rate and reduces mortality after thread-occlusion of the middle cerebral
artery in young or aged rats. J. Neur. Meth. 2006 155: 285-290.
19. K. Kitagawa, M. Matsumato et al. Cerebral Ischemia After Bilateral Carotid Artery
occlusion and Intraluminal Suture Occlusion in Mice: Evaluation of the Patency of the
Posterior Communicating Artery. J. Cereb. Blood Flow Metab. 1998 18:570-579.
20. T.N. Lin, Y.Y. He et al. Effect of brain edema on infarct volume in a focal cerebral
ischemia model in rat. Stroke 1993 24: 117-121.
21. R.C.G. Herz, C.M. Kasbergen et al. Rat middle cerebral artery occlusion by an
intraluminal thread compromises collateral blood flow. Brain Res. 1998 791:
223–228.
22. M. D. Ginsberg, R. Busto. Rodent Models of Cerebral Ischemia. Stroke 1989 20:
1627-1642.
23. E. Candelario-Jalil, N.H. Mhadu et al. Effects of the cyclooxygenase-2 inhibitor
nimesulide on cerebral infarction and neurological deficits induced by permanent
middle cerebral artery occlusion in the rat. J. Neuroinflammation 2005 18: 121-132.
24. A. Durukan, T. Tatlisumak: Acute ischemic stroke: Overview of major experimental
rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol.
Biochem. Behav. 2007 87:179–197.
25. S. Orta, S. Arter et al. Middle Cerebral Artery Occlusion of Rats: Pathological and
Neurological Evaluation of the Model. Turk. Neurosurg. 1999 9: 52-58.
26. J. B. Bederson, L.H. Pitts et al. Rat middle cerebral artery occlusion: evaluation of the
model and development of a neurologic examination. Stroke 1986 17: 472-476.
27. R. J. Laing, J. Jakubowski et al. Middle cerebral artery occlusion without craniectomy
in rats. Which method works best? Stroke 1993 24: 294-298.
28. S. Shimizu, R.P. Simon et al. Dimethylsulfoxide (DMSO) treatment reduces infarction
volume after permanent focal cerebral ischemia in rats. Neurosci. Lett. 1997
239:125–127.
29. R. Rivera, J. Chun. Biological effects of lysophospholipids. Rev. Physiol. Biochem.
Pharmacol. 2006 160: 25–46.
30. C. E. Heise, W.L. Santos et al. Activity of 2-Substituted Lysophosphatidic Acid (LPA)
Analogs at LPA Receptors: Discovery of a LPA1/LPA3 Receptor Antagonist Mol.
Pharmacol. 2001 60:1173–1180.